What Is TB-500?
TB-500 (Thymosin Beta-4 fragment) is classified as a thymosin beta-4 fragment peptide. Upregulates actin for cell migration and wound healing. Reduces inflammation, encourages new blood vessel growth, and supports stem cell maturation for tissue repair.
It is extensively evaluated in laboratory and clinical settings for its potential to drive muscle/tissue repair, flexibility, injury recovery. Researchers target TB-500 for its ability to interact with specific cellular and molecular pathways, making it a compound of significant interest across multiple therapeutic domains.
Research-only; well-tolerated in Phase I/II trials. Not FDA-approved for systemic use.
How Does TB-500 Work?
Upregulates actin for cell migration and wound healing. Reduces inflammation, encourages new blood vessel growth, and supports stem cell maturation for tissue repair.
At the molecular level, TB-500 operates through pathways characteristic of the Thymosin Beta-4 Fragment class. By interacting with target receptors and downstream signaling cascades, the compound initiates biological responses associated with muscle/tissue repair, flexibility, injury recovery.
Expected Research Timeline
Weeks 2–4
Improved range of motion; reduced recovery time after training
Months 2–3
Enhanced tissue repair; measurable improvement in chronic injury sites
Long-Term
Improved recovery baseline; potential stem cell mobilization benefits
What Does the Research Say?
The following are key findings from peer-reviewed studies on TB-500, indexed on PubMed and equivalent databases:
[1]Thymosin Beta-4 wound healing and inflammation
Malinda et al. demonstrate Tβ4 promotes wound healing via enhanced reepithelialization, collagen deposition, angiogenesis, and keratinocyte migration in animal models.
Evidence: preclinical[2]Thymosin β4 activates cardiac progenitor cells for myocardial repair
Smart et al. (Nature) show Tβ4 activates endogenous cardiac progenitor cells, initiating myocardial and vascular regeneration after systemic administration in mice.
Evidence: preclinical[3]Thymosin β4 Phase I safety study in healthy volunteers
Phase I clinical trial demonstrates recombinant Tβ4 is well-tolerated at multiple IV doses in healthy volunteers, with no dose-limiting toxicities or serious adverse events.
Evidence: moderate[4]Thymosin β4 promotes dermal healing in diverse models
Tβ4 accelerates dermal healing in normal, diabetic, steroid-treated, and aged animal models. Phase 2 results show modest efficacy in venous stasis and pressure ulcers.
Evidence: moderate[5]Thymosin β4 reduces cardiac fibrosis and scar formation
Wei et al. show Tβ4 reduces scar formation post-myocardial infarction by inhibiting ROCK1 signaling, promoting neovascularization, and activating cardioprotective pathways.
Evidence: preclinicalSafety & Side Effects
Research-only; well-tolerated in Phase I/II trials. Not FDA-approved for systemic use.
| Side Effect | Incidence | Severity |
|---|---|---|
| Injection site reaction | ~8% of users | mild |
| Transient fatigue | ~4% of users | mild |
| Headache | ~3% of users | mild |
FDA Status: Not Approved for Human Therapeutic Use
TB-500 is not currently FDA-approved for human use. It is available for research purposes only. Always consult a licensed healthcare provider.
How Is TB-500 Used?
Route
SubQ
Dose Range
2500–2500 mcg
Frequency
2x/wk
Cycle
8–8 wk
Timing: Any time
Notes: Loading phase: 5mg 2x/week for 4 weeks. Maintenance: 2.5mg 2x/week.
All dosing information reflects parameters reported in published research literature and is not intended as clinical guidance. Usage of any peptide should be supervised by a qualified healthcare professional.
TB-500 vs. Related Compounds
Where to Source TB-500 for Research
Purchasing ultra-high purity, laboratory-grade peptides is critical for verifiable research. We only recommend vendors providing independent, third-party HPLC Certificates of Analysis (COA).
Disclosure: PeptiDex may earn a commission from purchases. This does not affect our recommendations. We exclusively feature vendors that pass our strict quality verification protocols.
Frequently Asked Questions
What is TB-500?
TB-500 is a thymosin beta-4 fragment peptide. Upregulates actin for cell migration and wound healing. Reduces inflammation, encourages new blood vessel growth, and supports stem cell maturation for tissue repair.
What are the primary research benefits of TB-500?
Published research identifies primary mechanisms targeting: Muscle/tissue repair, flexibility, injury recovery. These findings come from 5+ peer-reviewed studies indexed in our database.
What is the half-life of TB-500?
In published pharmacokinetic data, TB-500 demonstrates a half-life of approximately 2 hours.
Is TB-500 FDA approved?
TB-500 is not currently FDA-approved for human therapeutic use. It is classified as a research compound and is studied under investigational protocols. Always consult a healthcare provider.
What are common side effects of TB-500?
Reported side effects in published literature include Injection site reaction (~8% of users), Transient fatigue (~4% of users), Headache (~3% of users). Most are classified as mild in severity.
How is TB-500 administered?
In research settings, TB-500 is typically administered via SubQ. Loading phase: 5mg 2x/week for 4 weeks. Maintenance: 2.5mg 2x/week.
Sources
- Thymosin Beta-4 wound healing and inflammation. View on PubMed
- Thymosin β4 activates cardiac progenitor cells for myocardial repair. View on PubMed
- Thymosin β4 Phase I safety study in healthy volunteers. View on PubMed
- Thymosin β4 promotes dermal healing in diverse models. View on PubMed
- Thymosin β4 reduces cardiac fibrosis and scar formation. View on PubMed